Our GLP-1 lawsuit lawyers are fighting to hold these pharmaceutical companies accountable for what we allege is a failure to adequately warn patients about these severe potential health risks
Who is Retatrutide 40 mg for Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA Triple GLP-1 / GIP / glucagon agonist a unique mechanism of action For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect Strictly under medical supervision Retatrutide 40 mg compared to other doses Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023) Compared to Mounjaro 15 mg (~2226%) a similar effect, but with a triple mechanism Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure No final Phase 3 results yet efficacy and safety are still being confirmed FAQ about Retatrutide 40 mg (ALLUVI) 1 ALLUVI Retatrutide injection pen (40 mg total, dial mechanism up to 10 mg per dose), 12 single-use ALLUVI needles and dosing instructions (Dosage Guide) with step-by-step schedule from 2.5 mg to 10 mg
Yes, doctors consider them safe for extended use when properly supervised
It does not work for everyone because CIDP is not the same disease in every person
Young, L., Drugs that stimulate oxytocin release promote social bonding in an animal model relevant to autism
